Circ Res：不含酒精的红酒或有助降低血压

美国心脏病协会杂志Circulation Research发表的一项研究称，有心脏病高风险的男性在连续四周每天喝不含酒精的红酒（non-alcoholic red wine）之后血压降低。

不含酒精的红酒可以提高参与者体内NO，这将有助于降低收缩压和舒张压。NO在体内的作用是促进血管松弛，使得更多的血液流向心脏和其他器官。

67位患有糖尿病或有三种及三种以上心血管风险因素疾病的男性参与了此项研究，在正常饮食的同时喝10盎司红酒或10盎司不含酒精的红酒或3盎司杜松子酒。其中红酒和不含酒精的红酒含有等量的可降低血压的多酚。

结果发现，每天喝红酒的人血压仅有少量降低，喝杜松子酒的人血压没有变化，而喝不含酒精红酒的人收缩压降低6mmHg，舒张压降低2mmHg，可降低心脏病风险14%，卒中风险20%。因此，研究者推测红酒中的酒精削弱了其降血压的功能，在除去酒精之后多酚便可发挥其降血压的功能。                   

拓展阅读：                         

doi:10.1161/CIRCRESAHA.112.275636
PMC:
PMID:

Dealcoholized Red Wine Decreases Systolic and Diastolic Blood Pressure and Increases Plasma Nitric Oxide

Gemma Chiva-Blanch1, Mireia Urpi-Sarda1, Emilio Ros2, Sara Arranz1, Palmira Valderas-Martinez1, Rosa Casas1, Emilio Sacanella3, Rafael Llorach4, Rosa M. Lamuela-Raventos5, Cristina Andres-Lacueva4 and Ramon Estruch1*

Rationale: Experimental studies have shown a potential blood pressure (BP) lowering effect of red wine polyphenols, while the effects of ethanol and polyphenols on BP in humans are not yet clear.

Objective: The aim of the present work was to evaluate the effects of red wine fractions (alcoholic and non-alcoholic) on BP and plasma nitric oxide (NO) in subjects at high cardiovascular risk.

Methods and Results: Sixty-seven men at high cardiovascular risk were studied. After a 2-week run-in period, subjects were randomized into three treatment periods in a cross-over clinical trial, with a common background diet plus red wine (30g alcohol/d), the equivalent amount of dealcoholized red wine, or gin (30g alcohol/d), lasting 4 weeks each intervention. At baseline and after each intervention, anthropometrical parameters, BP and plasma NO were measured. Systolic and diastolic BP decreased significantly after the dealcoholized red wine intervention and these changes correlated with increases in plasma NO.

Conclusions: Dealcoholized red wine decreases systolic and diastolic BP. Our results point out through a NO-mediated mechanism. The daily consumption of dealcoholized red wine could be useful for the prevention of low to moderate hypertension. Trial registered at controlled-trials.com: ISRCTN88720134.